• Journal of Pharmaceutical Investigation
• /
• v.29 no.3
• /
• pp.247-251
• /
• 1999

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2010.10a
• /
• pp.3-3
• /
• 2010

GM 들잔디의 환경위해성평가는 유전자변형생물체의 국가간이동등에 관한 법률 (2008년)에 안전관리 및 시험평가가 수행되었다. 일반적으로 GM 작물의 환경위해성평가는 도입 유전자의 안정적 발현여부, 일반적으로 사용되어온 식물과의 실질적 동등성, 화분비산에 의한 유전자이동성 검정, GM재배작물 주변 환경에 미치는 영향, GM작물 및 유전자의 인체 및 동물에 대한 안전성 평가, 위해성 관리 등이 있다. 본 발표에서는 제초제저항성 GM 들잔디를 실용화 하기위한 환경위해성평가의 내용을 소개하기 위하여 GM 들잔디의 안전성평가를 수행한 포장시험에 대해서 간략히 발표하고자 한다. GM 들잔디는 제초제저항성 유전자가 식물체내에 1개의 복제수를 갖으며, 후세대에서도 안정적으로 발현되었다. 또한 TAIL PCR을 통한 도입 유전자의 삽입 부위를 확인하였고, 주변염기서열을 이용한 JG21 들잔디 만의 특이적 염기서열을 얻었다. GM 들잔디의 실질적 동등성검정은 격리온실 수준과 격리포장 수준에 생물학적, 화학적 특성을 조사하였고, 일반 들잔디와 큰 차이가 없음을 확인하였다. GM 들잔디의 화분은 일광조건하에서 약 1시간 이내에 불활성 되었고, 실내의 실온조건에서는 3시간까지 활성이 유지되었다. GM 들잔디 재배포장 ($12m{\times}6m$ 크기)으로부터 화분비산 밀도는 3 m 이내에서 높게 나타났고, 9 m 이상의 거리에서는 낮은 빈도로 일정하게 나타났다. 화분비산에 의한 GM 들잔디 유전자이동성은 근접거리에서 약 15%가 관찰되었고, 반경 3 m 이내에서 거리에 따라서 2 ~ 0.12%의 유전자이동성이 관찰되었다. 각각의 시험모형에 따른 GM 들잔디와 일반들잔디 간의 교잡율을 조사한 결과 들잔디 교잡율은 GM 잔디의 면적과 거리에 의존적이었고, GM 들잔디 면적에 따라서 6-21%의 교잡율이 나타났다. GM들잔디의 인체위해성평가는 독성 및 알레르기 반응성을 검정하였고, 도입유전자 산물인 PAT 단백질은 독성 및 알레르기 반응성이 없음이 알려져 있다. 본 연구에서는 GM들잔디의 독성 및 알레르기 반응성을 검토한 결과 아플라톡신 등의 독성은 검출되지 않았으나, GM과 일반 들잔디 모두에서 화분 알레르기 반응성이 양성으로 나왔다. 그러나 GM들잔디에 도입된 유전자에 의한 알레르기 반응이 아닌 일반들잔디 화분에 가진 알레르겐에 의한 반응성이라 할 수 있다. GM들잔디의 비의도적 방출가능성을 조사하기위하여 시험포장외부의 자연환경에 대해서 환경모니터링을 수행한 결과 GM 들잔디의 유출 및 유전자이동 의한 제초제저항성 들잔디는 나타나지 않았다.

• The Korean Journal of Applied Statistics
• /
• v.24 no.4
• /
• pp.623-631
• /
• 2011

A major goal of time-course microarray data analysis is the detection of groups of genes that manifest similar expression patterns over time. The corresponding numerous cluster algorithms for clustering time-course microarray data have been developed. In this study, we proposed a clustering method based on the primary pharmacokinetic parameters in the pharmacokinetics study for assessment of pharmaceutical equivalents between two drug products. A real data and a simulation data was used to demonstrate the usefulness of the proposed method.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1995.10a
• /
• pp.157-160
• /
• 1995

라니티딘은 최근 위궤양 및 십이지장 궤양의 치료에 통상적으로 많이 처방되는 히스타민 H$_2$ receptor antagonist로 작용하는 약물이다. 이 약물의 Pharma-cokinetics에 대해서는 동물 및 사람에 있어서 이미 많은 연구가 되어 있다(1-4). 수용성 약물인 라니티딘은 정상인에 있어서 경구투여 후 흡수가 신속하나 불완전한 것으로 알려져 있다(4). 경구투여 후 개개인에 따른 처고 혈중농도(Cmax)가 상당히 큰 차이를 보이며, 생체내 이용률(Bioavailability)은 평균 50% 이나 최저 27%에서 최고 88%에 이르기까지 넓은 범위를 보이고 있다. 더욱이 공복 시 경구투여 하거나(5-8), jejunum에 직접 bolus 투여후(9) 혹은 심지어는 정맥주사후의 경우(10)에도 소위 'double-peak phenomenon'이라고 불리 우는 최고 혈중농도에 있어서 bimodal pattern을 나타낸다. 이처럼 highly variable한 약물들은 생물학적 동등성(Bioequivalence) 측면에서 제제를 평가할 때 상당히 중요하고도 어려운 과제이므로, 현재 세계적인 issue가 되고 있다.

• The Korean Journal of Pharmacology
• /
• v.26 no.2
• /
• pp.219-226
• /
• 1990

Enalapril maleate tablets of two different producers were tested for bioequivalence. Enalapril is rapidly metabolized to an active metabolite, enalaprilat which inhibits angiotensin-converting enzyme (ACE). The pharmacokinetics of enalapril maleate and the time course of inhibition of plasma ACE activity after administration of the drugs were studied. Two single doses of 10mg each of enalapril maleate were administered orally to twelve male volunteers in a balanced, randomized, two-way crossover investigation. Plasma enalaprilat concentrations were determined over a 23-hour after the dose by enzyme inhibition assay and enalapril by the same method following in vitro hydrolysis. Urinary recoveries of enalapril and enalaprilat were determined for the calculation of renal clearance. Plasma ACE activity was determined by an enzyme assay. Peak plasma levels of enalapril were observed about 1 hour after the doses, and practically all enalapril had disappeared from plasma within 6 hour. Peak enalapril concentrations of both formulations were almost identical ($Vasotec^{\circledR}$, 61.38 ng/ml; $Beartec^{\circledR}$, 64.27 ng/ml). The values of the pharmacokinetic parameters of enalaprilat computed for $Vasotec^{\circledR}$ and $Beartec^{\circledR}$ tablets are presented in that order; area under the curve=330.63:320.96 $ng{\cdot}hr/ml$; peak concentration=38.63:39.43 ng/ml; time to peak=3.83:4.08 hour; elimination half-life=3.95:3.92 hours. No statistically significant difference was detected when area under the curve and all other parameters were compared. Using criteria of 95% confidence interval for the comparison of these parameters, only the upper limits of area under the curve and time to peak of enalapril were over 120%. All the parameters of enalaprilat were acceptable. Percent inhibition of plasma ACE to plasma enalaprilat concentration showed the sigmoid concentration-inhibition relationship. Time courses of plasma ACE inhibition after the administration of both formulations were quite similar. The formulations were found to be equivalent when compared on the premise that no significant difference was detected when pharmacokientic parameters and inhibition of ACE activity were compared, based on the confidence limits analysis.

• Biomolecules & Therapeutics
• /
• v.5 no.3
• /
• pp.260-264
• /
• 1997

The bioequivalence of two nicotine patches was evaluated in 16 normal male volunteers (age 21 ~ 27 yrs) following single transdermal application. Test product was "Nicostop patch" made by Sam Yang Co. and reference product was "Nicotinell TTS patch" made by Korean Searle Ciba-Geigy Co. After nicotine patches were applied onto the inside of the forearm, blood was taken at predetermined time intervals and the nicotine concentration in plasma was determined with a sensitive GC method using NPD detector. AUC and Cm\ulcorner were calculated and statistically analyzed for the bioequivalence of the two products. The results showed that the differences in AUC and $C_{msx}$between two products were 5.47% and 2.70%, respectively. The powers (1-$\beta$) for AUC and $C_{max}$. were >90% and 88.76%, respectively. Detectable differences($\Delta$) and confidence intervals were all less than 20%. All of these parameters met the criteria of KFDA for bioequivalence, indicating that "Nicostop patch" is bioequivalent to "Nicotinell TTS patch" . . .

• Journal of Pharmaceutical Investigation
• /
• v.34 no.5
• /
• pp.379-383
• /
• 2004

Statistical interpretations in a bioequivalence trial are considered and studied when the missing observations occurred in $2\;{\times}\;2$ crossover experiment. Patel (1985) suggested the approximate test procedures for carryover effect and drug effect in $2\;{\times}\;2$ crossover design when some of data are missing in the second period. A modified Patel method is newly proposed to the bioequivalence trial and it is compared with the current method through the simulation study.

• YAKHAK HOEJI
• /
• v.34 no.5
• /
• pp.334-340
• /
• 1990

The bioequivalence of Mandol and Mancef (cefamondole nafate injection preparation) was investigated for 8 healthy human volunteers. Cefamandole nafate hydrolysis to cefamandole base in the blood and shows antibacterial activity. As the rate of the hydrolysis can be varied according to the buffer used in the preparation, the bioequivalence of cefamandole nafate I.V. was studied. A new HPLC method, the column switching technique, was developed and used for the simultaneous determination of cefamandole and cefamandole nafate in the plasma and in the urine. There were no statistically significant difference in between Mandol and Mancef for the parameters of AUC and Cp 0.25 hr even through the power of the test was not enough.

• Biomolecules & Therapeutics
• /
• v.6 no.4
• /
• pp.417-422
• /
• 1998

Loxoprofen sodium (sodium 2-[4-(2-oxocyclopentylmethyl)phenyl] propionate dehydrate) is a nonsteroidal antiinflammatory drug of $\alpha$-phenyl propionic acid derivative. To test the bioequivalence of loxoprofen, the pharmacokinetic parameters of new preparation of loxoprofen, LENOX was compared with LOXONIN as a reference drug. Fourteen healthy volunteers were entered to the stydy (Yonsei University College of Medicine, Severance Hospital IRB approval No. 9608). They were administered 60 mg of loxoprofen in 2$\times$2 cross-over design. There was one week of drug-free interval between doses. The blood sample was taken on schedule up to 8 hours, and the plasma concentration loxoprofen was measured by reverse phase high-performance liquid chromatography (HPLC) with UV-detector. There were no significant difference between two preparations when AUC, Cmax, and Tmax were compared by ANOVA. The mean differences of AUC, Cmax, and Tmax were within 20% of the reference drug: the values were 2.22,5.61, and 12.50%, respectively. The confidence limits of AUC and Cmax but not Tmax satisfied the bioequivalence criteria. These results suggest that the tested LENOX is bioequivalent to the reference drug.

• Journal of Pharmaceutical Investigation
• /
• v.24 no.2
• /
• pp.49-55
• /
• 1994

Bioequivalence test of commercially available rifampicin capsules was performed. Sixteen volunteers were divided into 2 groups and the reference and test drug were given orally (450 mg) by cross-over design. Statistical evaluation of AUC, $C_{max}\;and\;T_{max}$ involved an analysis of variance (ANOVA). The differences of mean value in AUC, $C_{max}\;and\;T_{max}$ between the reference and test drug were within 20% with reference drug. ANOVA showed no significant differences for ‘between group’, ‘drug’ and ‘period’, but not for ‘between subjects’. The power of test $(1-{\beta})\;of\;AUC\;and\;$C_{max}$ was larger than 0.8 and the confidence of bioavailability was $within\;{\pm}20%$. From these results, it was concluded that the two preparations were bioequivalent for AUC and $C_{max}$, but was not for $T_{max}$.